Holiday greetings and an end-of-year update on our innovative breast cancer diagnostic test in development.
The holiday season is a time to celebrate, but also a time to give thanks and to reflect on our accomplishments of the past year.
The Ascendant Diagnostics team is proud of the significant progress we have made with our Melody Dx™ research project. Melody Dx is a tear-based diagnostic screening test for early detection of breast cancer, which Ascendant is currently in the process of developing. This test is a patent-pending biomarker panel, which distinguishes differences in proteins present in tears in order to detect breast cancer.
The goal of our diagnostic screening tool is to increase breast cancer detection at earlier stages while also reducing unnecessary exposure to radiation and painful biopsy procedures. To date, the biggest challenge to increasing the survival rate from breast cancer is accurate early detection.
Ascendant conducted clinical studies with five clinics nationwide during 2013. These clinics collected tears from patients being treated for breast cancer (and other cancers) and those coming in for biopsy analysis. Tear samples were also collected from women outside the clinics for general population studies, a step necessary for commercializing a diagnostic test.
In 2014, additional clinics will begin collecting tear samples and other initiatives will be launched to increase the number of samples in our “tear bank” for general population studies. In the new year, we will also announce other exciting developments including a strategic partnership, new state-of-the-art equipment and software, and additional professional staff to help successfully bring our innovative diagnostic test to market.
In the first quarter of 2014, we will unveil a new company logo and launch our newly-designed website. We’ll continue to update you on the progress of our groundbreaking research and also bring you articles of interest about breast cancer screening and diagnosis.
Currently, the most effective screening method available for breast cancer is mammography. This article http://www.celebritydiagnosis.com/2013/11/abc-news-amy-robach-diagnosed-breast-cancer/ is on the website "Celebrity Diagnosis: Teachable Moments in Medicine™." It tells an interesting story of an ABC news correspondent unexpectedly diagnosed with breast cancer and also provides suggested mammography screening guidelines.
Mammography is an important screening tool, however Ascendant Diagnostics believes there is a potential for innovative new screening techniques to substantially increase the accuracy of breast cancer diagnostics, enable detection of disease at the earliest possible stage and improve patient compliance.
We end 2013 on that hopeful note and will continue to pursue our fight against breast cancer with additional resources and vigor in 2014 and beyond.
Sending you and yours best wishes for good health, happiness and fulfillment in the coming year.
Chief Executive Officer, Ascendant Diagnostics